Prescriber Scope of Practice for Weight Loss/GLP-1

If you’re a psychiatrist considering adding weight management to your telehealth practice — or a PMHNP wondering if you can prescribe GLP-1s for patients struggling with antipsychotic-induced weight gain — you’re navigating one of the most confusing regulatory intersections in healthcare right now.

Here’s the reality: Yes, psychiatrists can legally prescribe weight-loss medications including GLP-1 agonists and controlled appetite suppressants via telehealth in most states. But the rules vary wildly by state, the type of medication, and your provider credentials. Get it wrong, and you’re risking medical board scrutiny or worse.

This guide cuts through the noise with what you actually need to know about telehealth prescribing regulations for weight loss medications in 2026 — including the DEA’s current stance, state-by-state differences, and the business case for adding this service to your practice.

The Federal Picture: What the DEA’s 2026 Extension Actually Means

Let’s start with the elephant in the room: Can you prescribe controlled substances like phentermine (Adipex) via telehealth without seeing patients in person?

Yes — through December 31, 2026. The DEA and HHS just extended COVID-era telehealth flexibilities for the fourth time, allowing providers to prescribe Schedule II–V controlled substances to new patients via telemedicine without a prior in-person exam. This buys the industry nearly two more years while permanent regulations are finalized.

The catch? This is explicitly temporary. The DEA is developing new rules that will likely require either a ‘special telemedicine registration’ or impose restrictions like initial 30-day supply limits for remote prescribing of certain controlled drugs. Public comment periods suggest they’re considering requiring tele-prescribers to be located in the same state as patients and potentially capping the percentage of your practice that can be pure telehealth.

For weight loss specifically:

• GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound, liraglutide/Saxenda) are not controlled substances — you can prescribe them via telehealth indefinitely as long as you meet standard prescribing guidelines
• Phentermine (Schedule IV) and other appetite suppressants are controlled — currently prescribable via telehealth under the federal extension, but subject to state overrides (more on that below)
• Combination drugs like phentermine/topiramate (Qsymia) follow the same Schedule IV rules

Bottom line: If you’re building a telehealth weight-loss practice around GLP-1s, federal DEA rules aren’t your obstacle. If you’re including controlled appetite suppressants, you’re operating on borrowed time unless you have a plan for when federal rules tighten in 2027.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Rules That Override Federal Flexibility

Here’s where it gets messy. Several states have enacted their own in-person exam requirements for controlled substances that are stricter than current federal law.

New York: The Strictest Approach

New York currently requires at least one in-person medical evaluation before prescribing any controlled substance to a patient (10 NYCRR §80.63, updated May 2025).

Limited exceptions:

• Another NY-licensed provider examined the patient in person within the last 12 months and shared records
• You’re covering for a colleague who saw the patient in person
• Emergency situation with existing patient (max 5-day supply)

What this means: A New York-based psychiatrist cannot start a patient on phentermine via pure telehealth. You either need to see them in person once, coordinate with their PCP who saw them recently, or skip controlled substances entirely and stick to GLP-1s.

For non-controlled weight-loss meds: NY allows full telehealth prescribing with no in-person requirement as long as the exam meets standard of care (video preferred, audio-only permitted for mental health in some cases).

Florida: Carve-Outs for Psychiatry

Florida prohibits teleprescribing Schedule II controlled substances except for psychiatric treatment, inpatient care, hospice, or nursing home residents (Fla. Stat. §456.47).

What this means:

• Psychiatrists can prescribe Adderall or other Schedule II ADHD meds via telehealth (psychiatric disorder exception)
• Weight-loss prescribing of Schedule II drugs is NOT allowed via telehealth (obesity isn’t a psychiatric disorder)
• Phentermine (Schedule IV) is NOT restricted — you can prescribe it via telehealth for weight loss in Florida
• GLP-1s are unrestricted — telehealth is explicitly permitted

Florida’s additional weight-loss requirements:

• Document BMI ≥30 (or ≥27 with comorbidities)
• Obtain written informed consent outlining medication risks
• Re-evaluate patients at least every 3 months
• Provide the state-mandated ‘Weight-Loss Consumer Bill of Rights’
• Check the E-FORCSE PDMP before prescribing any controlled substance

Texas, California, Pennsylvania, Illinois: More Permissive

These states generally allow telehealth prescribing of controlled substances under the current federal extension, with nuances:

California:

• No state ban on telehealth controlled substance prescribing
• Must check CURES PDMP before first fill of any Schedule II–IV and every 4 months thereafter
• Requires documented patient consent for telehealth (BPC §2290.5)
• All prescriptions must be e-prescribed

Texas:

• Accepts telehealth exams (live video or store-and-forward with audio) as valid patient relationship
• Must use Tx PMP for controlled substances (mandatory for opioids/benzos, best practice for all)
• Requires follow-up care plan and, with patient consent, report to PCP within 72 hours

Pennsylvania:

• No state-level in-person requirement for controlled substances (defers to federal law)
• Must check PA PDMP before first opioid/benzo prescription and each time thereafter
• Recommends PDMP checks for all controlled substances

Illinois:

• Explicit permission for telehealth to establish patient relationships
• No in-person mandate; even audio-only allowed in some cases
• PDMP checks required for Schedule II narcotics; best practice for all controlled substances

Psychiatrist vs PMHNP Scope: Who Can Actually Do This?

Psychiatrists (MD/DO)

You have broad legal authority to prescribe weight-loss medications. Your unrestricted medical license covers treating obesity, even though it’s not your specialty.

The standard: You must practice competently and follow applicable standard of care. State medical boards will hold you to the same expectations as any physician treating obesity.

Practical considerations:

• Document BMI, comorbidities, and informed consent like any obesity specialist would
• Consider interactions between weight-loss meds and psychiatric medications (e.g., phentermine’s stimulant effects in patients with anxiety or bipolar disorder)
• Be prepared to provide or coordinate nutrition counseling and lifestyle modification (many states like New Jersey explicitly require this)
• Schedule appropriate follow-ups (quarterly minimum in Florida, monthly recommended early in treatment nationally)

Risk mitigation: Some psychiatrists pursue additional certification through the American Board of Obesity Medicine (ABOM) to bolster credibility and demonstrate competence. Not required legally, but smart defensively.

Psychiatric Mental Health Nurse Practitioners (PMHNPs)

This is where scope gets tricky. Your PMHNP certification is in mental health, not metabolic or primary care. Prescribing purely for obesity may be viewed by some state nursing boards as outside your scope of practice.

State-by-state reality:

States requiring physician collaboration/supervision:

• Texas, Florida (for most PMHNPs): You need a supervising physician’s sign-off to manage weight loss. Ideally, that physician should have expertise in obesity medicine (family practice or endocrinology), not just psychiatry
• Pennsylvania: Require Collaborative Agreement that specifically includes weight-loss protocols
• California: Operate under Standardized Procedures with MD supervision unless you qualify for independent practice under AB 890 (phases in through 2026)

States with Full Practice Authority (FPA):

• Illinois: APRNs with 4,000+ hours experience can practice independently, but you’re still expected to practice within your competence — treating obesity as a psych NP might raise questions
• New York: After 3,600 hours, NPs can practice without formal collaborative agreements but must maintain ‘collaborative relationships’ and refer appropriately

The smart approach for PMHNPs:

• If treating weight gain related to psychiatric medications: You’re on solid ground — this is clearly within psych scope (e.g., prescribing metformin or a GLP-1 to offset olanzapine-induced weight gain)
• If running a pure weight-loss practice: Get explicit physician collaboration (preferably with an obesity specialist) or pursue additional certification (e.g., WHNP or FNP credentials, or obesity medicine training)
• Document the psychiatric connection: If treating patients with binge eating disorder, depression affecting motivation, or medication-induced weight gain, you have a stronger scope argument

The Economics: Why Weight Loss Makes Sense for Psychiatric Practices

Let’s talk business. Adding weight management to your telehealth psychiatry practice isn’t just about scope creep — it’s about patient demand and revenue diversification.

The market reality:

• 42% of U.S. adults have obesity (CDC data)
• GLP-1 drugs have created unprecedented consumer demand (Google searches for ‘Ozempic’ up 3,500% since 2021)
• Many primary care practices have 3–6 month waitlists for weight management
• Psychiatric patients are disproportionately affected by weight gain (antipsychotics, mood stabilizers, antidepressants all contribute)

Revenue potential:

• GLP-1 programs: Typical cash-pay telehealth weight-loss programs charge $150–300/month for provider visits plus medication (patient pays separately or via subscription)
• Insurance billing: If covered, expect $100–150 per visit for obesity counseling/management (CPT 99213–99214 with diagnosis code E66.x)
• Patient volume: A psychiatrist seeing 2–3 weight-loss patients per week via telehealth = $15,000–25,000 additional annual revenue
• Continuity advantage: You’re already seeing these patients for mental health — adding weight management creates stickier patient relationships and better outcomes

Patient acquisition cost reality:

Here’s where most provider marketing content gets it wrong. Acquiring a qualified psychiatric or weight-loss patient through traditional marketing channels costs $200–500+ per patient when you factor in ALL costs:

• Google Ads for ‘weight loss doctor’ or ‘psychiatrist near me’ cost $15–40+ per click; most clicks don’t convert to booked patients
• SEO takes 6–12 months of consistent investment ($2,000–5,000/month for competitive markets) before generating meaningful patient flow
• Directory listings (Psychology Today, Zocdoc) charge monthly subscriptions ($100–300) PLUS per-booking fees ($35–100+)
• Agency/consultant fees add another 20–30% on top
• No-show rates from cold leads waste 15–30% of appointment slots
• Staff time to qualify and schedule leads is often uncounted

The platform economics alternative: Services like Klarity Health use a pay-per-appointment model — you pay a standard listing fee only when a pre-qualified patient books with you. No upfront marketing spend. No monthly subscriptions. No wasted ad budget on clicks that don’t convert.

For most providers, especially those starting out or scaling quickly, paying a known fee per qualified patient beats gambling $3,000–5,000/month on marketing channels with uncertain ROI. You’re guaranteeing ROI vs hoping your SEO or PPC eventually works.

Compliance Checklist: Covering Your Bases

Whether you’re prescribing GLP-1s or controlled substances via telehealth, here’s your non-negotiable compliance checklist:

Licensure & Platform

• [ ] Licensed in every state where patients are located
• [ ] Using HIPAA-compliant video platform
• [ ] Documented telehealth consent (required in CA, IL, recommended everywhere)
• [ ] E-prescribing system with EPCS certification (required in NY, CA, IL, TX for controlled substances)

Patient Evaluation

• [ ] Live video exam (audio-only insufficient for initial weight-loss evaluation in most states)
• [ ] Documented weight/BMI and eligibility criteria (BMI ≥30 or ≥27 with comorbidities)
• [ ] Screening for contraindications (cardiovascular disease, pregnancy, eating disorders, thyroid issues)
• [ ] For controlled substances: PDMP check completed and documented
• [ ] For psychiatric patients: Assessment of how weight-loss meds might interact with psych medications

Informed Consent & Documentation

• [ ] Written informed consent outlining risks, benefits, alternatives (required in FL, best practice everywhere)
• [ ] Documentation of diet/exercise counseling or referral (required in NJ, expected nationally)
• [ ] Treatment plan with follow-up schedule
• [ ] For FL providers: ‘Weight-Loss Consumer Bill of Rights’ provided to patient

Follow-Up & Monitoring

• [ ] Follow-up visits at least every 3 months (FL requirement; monthly recommended for GLP-1 initiation)
• [ ] Monitoring of weight, blood pressure, heart rate, side effects
• [ ] Lab monitoring as appropriate (glucose, thyroid function, liver enzymes depending on medication)
• [ ] Coordination with patient’s PCP (TX requires report within 72 hours with patient consent)

State-Specific Requirements

• [ ] New York: In-person exam completed or coordinated if prescribing controlled substances
• [ ] Florida: Quarterly re-evaluations, Consumer Bill of Rights, written consent, PDMP checks
• [ ] California: CURES PDMP checks every 4 months, telehealth consent documented
• [ ] Texas: PMP checks for controlled substances, follow-up plan provided
• [ ] Pennsylvania: PDMP checks for benzos/opioids each time

FAQ: Your Top Questions Answered

Can I prescribe Ozempic (semaglutide) for weight loss via telehealth?

Yes, in virtually all states. Semaglutide is FDA-approved for weight management (branded as Wegovy; Ozempic is the diabetes formulation often used off-label). It’s not a controlled substance, so federal DEA rules don’t apply. You need:

• Appropriate telehealth exam meeting state standard of care
• Documentation of BMI ≥30 or ≥27 with weight-related comorbidity
• Informed consent about GI side effects, injection technique, etc.
• State licensure where patient is located

Can I prescribe phentermine without an in-person visit?

Depends on your state:

• New York: No (requires in-person exam or coordination with provider who saw patient in person)
• Florida, Texas, California, Pennsylvania, Illinois: Yes, under current federal DEA extension through December 2026
• All states: Must check PDMP, use video exam, document standard of care evaluation

As a PMHNP, can I run a weight-loss telehealth practice?

Carefully, and ideally with physician collaboration. Your scope is mental health, not primary care/metabolic medicine. Safest approaches:

• Frame it as treating psychiatric medication-induced weight gain (clearly within scope)
• Establish physician collaboration agreement with an obesity specialist or family medicine doc who can oversee protocols
• Pursue additional training/certification in obesity medicine to demonstrate competence
• Practice in an FPA state (like Illinois or New York post-3,600 hours) to reduce barriers, but still coordinate with appropriate specialists

Do I need to be board-certified in obesity medicine?

No, but it helps. Any licensed physician can legally treat obesity. Board certification through ABOM demonstrates:

• Specialized knowledge (helpful if medical board ever reviews your care)
• Commitment to quality (good marketing differentiator)
• Reduced liability risk (shows you’re practicing within recognized standards)

For psychiatrists expanding into weight management, ABOM certification is a smart defensive move but not a legal requirement.

What happens when the DEA’s telehealth extension expires in December 2026?

Two likely scenarios:

1. New permanent rules are finalized before the extension expires, establishing clear pathways for telemedicine prescribing of controlled substances (probably requiring special registration or state-matching)
2. Another extension is granted while rules are still being developed (this has happened four times already)

What you should do now:

• Build your practice around non-controlled medications (GLP-1s) as the foundation
• If using controlled substances (phentermine), have a backup plan: either transition patients to in-person visits for medication management or switch to non-controlled alternatives
• Monitor DEA proposed rulemaking (watch for Federal Register notices in 2026)
• Join professional associations that lobby for permanent telehealth access (APA, AMA, AANP)

Is there higher regulatory risk with telehealth weight-loss prescribing?

Yes — this area is under scrutiny. State medical boards and consumer protection agencies are watching online weight-loss services for:

• Prescribing without adequate evaluation
• Lack of appropriate follow-up
• Misleading advertising (‘guaranteed weight loss,’ false FDA claims)
• Using compounded medications without proper disclosure
• Poor continuity of care

A 2025 survey found 52% of primary care physicians warn patients about risks of telehealth GLP-1 prescribers, citing concerns about ‘clinically inappropriate’ prescribing and inadequate monitoring.

How to reduce risk:

• Document thoroughly (evaluation, informed consent, follow-ups)
• Coordinate with patients’ primary care providers
• Follow state-specific protocols religiously (especially FL’s quarterly follow-ups, NJ’s counseling requirements)
• Use FDA-approved medications (avoid unregulated compounded semaglutide unless you understand the legal exposure)
• Set realistic patient expectations (no guaranteed results, lifestyle modification required)

The Bottom Line: Should You Add Weight Management to Your Telehealth Practice?

If you’re a psychiatrist, adding weight management — especially for patients experiencing medication-induced weight gain — is a natural extension of comprehensive psychiatric care. The regulatory path is clear (you’re legally authorized), the patient need is urgent (42% of Americans have obesity, higher in psychiatric populations), and the business case is strong (additional revenue stream, improved patient outcomes and retention).

If you’re a PMHNP, tread more carefully. Stick to patients where there’s a clear psychiatric connection (medication side effects, binge eating disorder, depression complicating weight loss), establish physician collaboration for protocols, and document your competence through training or additional certification.

Either way, the key is knowing your state’s rules and building compliance into your practice from day one. The opportunity is real — telehealth weight management is one of the fastest-growing segments in healthcare — but only for providers who do it right.

Ready to add qualified weight-loss patients to your telehealth practice without the marketing headache? Klarity Health connects psychiatrists and PMHNPs with pre-screened patients seeking both mental health and metabolic support — with built-in telehealth infrastructure, insurance and cash-pay options, and a pay-per-appointment model that eliminates marketing risk. You control your schedule and only pay when you see patients.

Explore how Klarity’s provider network can help you scale your telehealth practice while staying fully compliant with state regulations.

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (Jan 2, 2026) – Official policy announcement. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act) (2019, accessed Nov 2025) – Official state statute governing telehealth in Florida. http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity (Effective Aug 8, 2022) – Official Florida Board of Medicine regulation. https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (Mar 30, 2024) – Law firm analysis of state-specific weight-loss prescribing rules. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery – ‘Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers’ (Sept 29, 2023) – Legal analysis focused on Florida compliance. https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting – ‘California Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (2025) – State-specific compliance guidance for California. https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (2025) – Texas-specific compliance overview. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York Codes, Rules & Regulations Title 10, §80.63 – NY DOH Regulation on Prescribing (Amended May 2025) – Official New York regulation on controlled substance prescribing requirements. https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. Fierce Healthcare – ‘Primary care doctors concerned about telehealth GLP-1 boom: survey’ by Heather Landi (Feb 13, 2025) – News report on physician concerns about telehealth weight-loss prescribing. https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

10. California Medical Association – ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (Dec 2, 2025) – Official announcement on California Medicaid coverage changes. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

11. Center for Connected Health Policy – ‘State Telehealth Policies for Online Prescribing’ (Updated Nov 21, 2025) – Comprehensive database of state telehealth prescribing laws. https://www.cchpca.org/topic/online-prescribing/

12. Pennsylvania Department of Health – PDMP Prescriber FAQs (2022, accessed 2025) – Official guidance on Pennsylvania’s PDMP requirements. https://www.pa.gov/guides/prescription-drug-monitoring-program-pennsylvania/

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated